

Virtual Elimination of HCV from an inner city General Practice

Dr Kenneth Koh, Holdsworth House Medical Brisbane

Background

To understand treatment outcomes in the modern management of Hepatitis C (HCV) at Holdsworth House Medical Brisbane (HHMB) with HCV direct acting antivirals (DAA), an audit was performed of all HCV diagnoses.

Method

A search of all current and past HCV diagnoses on Medtech, the practice software, was done. Active patient records were identified for the audit. All treatments used and outcomes were noted and recorded.


Cases identified

90 cases identified
1 liver transplant, 1 not a regular patient, 1 had moved interstate, 1 deceased
= 86 active patients




Spontaneous Clearance

14 had spontaneously cleared HCV (16.3%)
= 72 chronic HCV (cHCV)




Interferon Treatment

21 had received interferon in the past 18 successful treatments
= 54 cHCV remaining




Specialist-initiated DAA

20 out of 20 achieved SVR 12
= 34 cHCV remaining



GP-initiated DAA

27 out of 29 achieved SVR (93.1%)



Final outcome

1 waiting for SVR
1 treatment failure
3 lost to follow up
1 deferred due to drug to drug interactions
1 not started treatment



DAA treatment experience in General Practice, initiated by GP

29 cases treated with GP-initiated direct acting antivirals
27 Achieved SVR (93.1%)


Gender	18 Male	11 Female
Age	23 – 66	mean 51.8

Genotype	1	3	4
Number	23	5	1

Fibrosis staging	Total	Only Modality	+ APRI / Fibroscan
APRI	13	8	5 (old)
Fibroscan	13	4	9

- 3 neither APRI/Fibroscan - 1 Child Pugh A, 1 Child Pugh B, 1 no information found
- 4 cirrhosis (Child-Pugh A, Child-Pugh B, Fibroscan x 2 (13.6 kPa, 11.2 kPa)
 - all achieved SVR
 - 8 HCV/HIV Coinfection
 - all achieved SVR

HHMB Treatment Cascade (cHCV)



Direct Acting Antivirals used

- 20 Sofosbuvir / Ledipasvir
- 4 Sofosbuvir / Daclatasvir
- 3 Sofosbuvir / Velpatasvir
- 2 Elbasvir / Grazoprevir